| HOME >> BIOLOGY >> TECHNOLOGY |
investments 188 5,612
Minority interest 463 3,912
Gain (loss) on investments in
equity securities (3) 775 12,788
Other (160) (525)
Investment income 14,870 16,219
Interest expense (1,655) (4,188)
Total other income (expenses) 14,481 33,818
Income (loss) before income taxes (1) 205,388 229,380
(Provision for) benefit from income
taxes (1) (60,117) (71,193)
Net income (loss) (1) $145,271 $158,187
Net income (loss) per share:
Basic $0.54 $0.60
Diluted (1,4) $0.52 $0.57
Weighted average shares outstanding:
Basic 267,276 263,476
Diluted (1,4) 285,208 279,924
(1) In accordance with the provisions of Financial Accounting Standards
Board, or FASB, Statement of Financial Accounting Standards No., or
FAS, 123R, "Share-Based Payment, an amendment of FASB Statement Nos.
123 and 95," we recorded pre-tax charges for stock-based compensation
expense and related tax benefits of:
Three Months Ended
March 31,
2008 2007
Cost of products and services sold $(6,514) $(5,896)
Selling, general and administrative
| SOURCE Genzyme Corp. Copyright©2008 PR Newswire. All rights reserved |